Jeffrey Herbert Hanke

Title: The Innovations of Jeffrey Herbert Hanke

Introduction

Jeffrey Herbert Hanke is a notable inventor based in Reading, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 10 patents to his name, Hanke's work has had a profound impact on medical research and therapeutic applications.

Latest Patents

One of Hanke's latest patents involves the creation of fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). This invention provides nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules. Specifically, it includes contiguous heavy and light chain sequences that span the complementarity determining regions (CDRs). The patent also covers antibodies with similar binding properties and functionality as those disclosed in his work.

Career Highlights

Throughout his career, Hanke has worked with prominent companies in the biotechnology sector, including Pfizer Corporation and Amgen Fremont Inc. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in immunology.

Collaborations

Hanke has collaborated with several professionals in his field, including Douglas Charles Hanson and Mark Joseph Neveu. These partnerships have facilitated the advancement of his research and the successful development of innovative therapies.

Conclusion

Jeffrey Herbert Hanke's contributions to the field of biotechnology, particularly through his patents on human monoclonal antibodies, highlight his role as a leading inventor. His work continues to influence medical research and therapeutic strategies, showcasing the importance of innovation in healthcare.